Back to Agenda
S34 : How should be Reguratory Document for Innovative Drug Development and Effective Drug Application Review in Society 5.0 Era?
Session Chair(s)
Kazuhiko Mori, PhD, MSc
Business Manager, "Toyama, the Silicon Valley of Medicine" Creative Consortium Management Office, Japan
Speaker(s)
How should be Regulatory Document for Innovative Drug Development and Effective Drug Application Review in Society 5.0 Era?
Tsuyoshi Ishiki
Global Scientific Communications Japan - , Eli Lilly Japan K.K., Japan
Yuki Ando, PhD
Principal Senior Scientist for Biostatistics, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Initiatives and Challenges in Generative AI Utilization
Kazumitsu Kanatani
Head, Digital Strategy Dept, Digital Transformation Unit., Chugai Pharmaceutical Co., Ltd., Japan
Utilization of Accumulus Synergy and Expectation from Pharmaceutical Campany
Takayuki Imaeda, MPharm, MS
Head of Regulatory Sciences, Pfizer R&D Japan, Japan
Mamoru Narukawa, PhD, RPh
Professor, Kitasato University, Japan
Have an account?